Clinical Trial Update: A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China

View source ↗

Summary

This update indicates the completion of a clinical trial evaluating lanadelumab (Takhzyro) and icatibant (Firazyr) for hereditary angioedema in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Firazyr (icatibant)
• Takhzyro (lanadelumab)

Snippet

Sponsor: Takeda | Conditions: Hereditary Angioedema (HAE) | Status: COMPLETED